Givinostat Demonstrates Positive Phase 3 Trial Results

Italfarmaco released positive topline data from their Phase 3 trial in Givinostat, an anti-fibrotic for use in ambulant boys with Duchenne over 6 years old and on a chronic steroid regimen. This new data reinforces a previously observed safety profile for Givinostat and adds to a growing dataset collected over the past few years which shows a good tolerability profile and positive outcomes for the cohort.

Read more in Italfarmaco’s press release:

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.